A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

[1] Goldstone AH(2001)Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 1302-1311

[2] Burnett AK(2002)Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study Blood 100 3869-3876

[3] Wheatley K(2015)Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein Pharmacol Ther 153 25-35

[4] Smith AG(2014)Clinical translation of nuclear export inhibitors in cancer Semin Cancer Biol 27 74-86

[5] Michael Hutchinson R(2016)Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia J Clin Oncol 34 4094-4101

[6] Clark RE(2013)Prognostic impact and targeting of CRM1 in acute myeloid leukemia Blood 121 4166-4174

[7] Anderson JE(2014)Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents J Hematol Oncol 7 78-1773

[8] Kopecky KJ(2012)Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia Blood 120 1765-199

[9] Willman CL(2016)Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice Leukemia 30 190-3174

[10] Ishizawa J(2017)A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia Blood 129 3165-6152

[1] Goldstone AH(2001)Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 1302-1311

[2] Burnett AK(2002)Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study Blood 100 3869-3876

[3] Wheatley K(2015)Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein Pharmacol Ther 153 25-35

[4] Smith AG(2014)Clinical translation of nuclear export inhibitors in cancer Semin Cancer Biol 27 74-86

[5] Michael Hutchinson R(2016)Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia J Clin Oncol 34 4094-4101

[6] Clark RE(2013)Prognostic impact and targeting of CRM1 in acute myeloid leukemia Blood 121 4166-4174

[7] Anderson JE(2014)Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents J Hematol Oncol 7 78-1773

[8] Kopecky KJ(2012)Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia Blood 120 1765-199

[9] Willman CL(2016)Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice Leukemia 30 190-3174

[10] Ishizawa J(2017)A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia Blood 129 3165-6152